JP2018506980A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506980A5
JP2018506980A5 JP2017543944A JP2017543944A JP2018506980A5 JP 2018506980 A5 JP2018506980 A5 JP 2018506980A5 JP 2017543944 A JP2017543944 A JP 2017543944A JP 2017543944 A JP2017543944 A JP 2017543944A JP 2018506980 A5 JP2018506980 A5 JP 2018506980A5
Authority
JP
Japan
Prior art keywords
cell
viral vector
composition
capsid protein
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543944A
Other languages
English (en)
Japanese (ja)
Other versions
JP6873907B2 (ja
JP2018506980A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018970 external-priority patent/WO2016134375A1/en
Publication of JP2018506980A publication Critical patent/JP2018506980A/ja
Publication of JP2018506980A5 publication Critical patent/JP2018506980A5/ja
Application granted granted Critical
Publication of JP6873907B2 publication Critical patent/JP6873907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543944A 2015-02-20 2016-02-22 遺伝性眼疾患を治療するための方法及び組成物 Active JP6873907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118934P 2015-02-20 2015-02-20
US62/118,934 2015-02-20
PCT/US2016/018970 WO2016134375A1 (en) 2015-02-20 2016-02-22 Methods and compositions for treating genetic eye diseases

Publications (3)

Publication Number Publication Date
JP2018506980A JP2018506980A (ja) 2018-03-15
JP2018506980A5 true JP2018506980A5 (enExample) 2019-04-04
JP6873907B2 JP6873907B2 (ja) 2021-05-19

Family

ID=56689466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543944A Active JP6873907B2 (ja) 2015-02-20 2016-02-22 遺伝性眼疾患を治療するための方法及び組成物

Country Status (12)

Country Link
US (1) US10472650B2 (enExample)
EP (1) EP3261440B1 (enExample)
JP (1) JP6873907B2 (enExample)
KR (1) KR102655319B1 (enExample)
CN (1) CN108347932B (enExample)
AU (1) AU2016219789B2 (enExample)
CA (1) CA2977355A1 (enExample)
ES (1) ES2920850T3 (enExample)
SA (1) SA517382162B1 (enExample)
SG (1) SG11201706755SA (enExample)
WO (1) WO2016134375A1 (enExample)
ZA (1) ZA201705628B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
IL262207B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
CN109640949B (zh) 2016-07-29 2022-11-25 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
WO2018045347A1 (en) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
KR20250023600A (ko) * 2017-06-30 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020001997A (es) 2017-08-28 2020-07-20 Univ California Variantes de capside de virus adenoasociado y metodos de uso de estas.
AU2018350700B2 (en) * 2017-10-16 2025-04-24 VeonGen Therapeutics GmbH AAV vectors
BR112020009329A2 (pt) * 2017-11-13 2020-10-13 The Regents Of The University Of California composições e métodos para melhorar a função visual
EP3714055A1 (en) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
AU2019220368B2 (en) * 2018-02-15 2024-06-13 Brave Bioscience Ab Modified viral capsids
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
US12421525B2 (en) 2018-02-28 2025-09-23 University of Pittsburgh—of the Commonwealth System of Higher Education Conjugates comprising AAVs and CAS9 polypeptides
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019241486A1 (en) 2018-06-13 2019-12-19 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
AU2019354793A1 (en) 2018-10-05 2021-05-13 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding AAV production proteins
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2020081490A1 (en) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
CA3125770A1 (en) 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
BR112021020101A2 (pt) * 2019-04-08 2022-02-15 Childrens Hospital Philadelphia Tratamento para doença de armazenamento lisossomal no olho através da administração de aavs expressando tpp1
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
CN114729009A (zh) * 2019-10-31 2022-07-08 伯尔尼大学 用于眼部基因递送的aav载体变体
CN115023242B (zh) 2019-11-22 2025-03-14 费城儿童医院 腺相关病毒载体变体
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
US20230277685A1 (en) * 2020-04-08 2023-09-07 President And Fellows Of Harvard College TGFß THERAPY FOR OCULAR AND NEURODEGENERATIVE DISEASES
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
AU2021313839A1 (en) * 2020-07-21 2023-03-23 FTGEN Corp Composition and method for treating eye diseases
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN113121655B (zh) * 2021-04-19 2021-11-19 上海信致医药科技有限公司 眼部和肌肉特异靶向型腺相关病毒载体及其应用
AU2022266615A1 (en) * 2021-04-27 2023-11-09 The General Hospital Corporation Aav capsids and uses thereof
US20240382617A1 (en) * 2021-09-21 2024-11-21 Capsida Biotherapeutics, Inc. Virus compositions to efficiently target the nervous system and the lungs
CA3238867A1 (en) 2021-11-29 2023-06-01 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
CN114195859B (zh) * 2021-12-10 2022-11-18 和元生物技术（上海）股份有限公司 一种适用于特异感染u251细胞的腺相关病毒突变体
KR20240152351A (ko) 2022-02-17 2024-10-21 스카이라인 테라퓨틱스 리미티드 변형된 aav 캡시드 폴리펩티드를 갖는 재조합 아데노-연관 바이러스
WO2023155918A1 (zh) 2022-02-21 2023-08-24 上海瑞宏迪医药有限公司 Vegf结合分子及其医药用途
WO2024017387A1 (en) * 2022-07-22 2024-01-25 Shanghai Vitalgen Biopharma Co., Ltd. Novel aav capsids for targeting nervous system and uses thereof
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024207061A1 (en) * 2023-04-04 2024-10-10 Children's Medical Research Institute Aav capsids and vectors for transduction of cells of the peripheral nervous system
TW202508610A (zh) 2023-08-23 2025-03-01 大陸商上海瑞宏迪醫藥有限公司 醫藥組成物及其用途
WO2025214408A1 (en) 2024-04-10 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Optogenetic modulation for vision restoration
WO2025214404A1 (en) 2024-04-10 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Optogenetic modulation for vision restoration
WO2026005189A1 (ko) * 2024-06-27 2026-01-02 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터
KR102901502B1 (ko) * 2024-06-27 2025-12-18 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터
CN119039401B (zh) * 2024-08-19 2025-04-11 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
US6943153B1 (en) * 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
WO2009108274A2 (en) 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
KR101154374B1 (ko) * 2009-02-18 2012-07-09 재단법인 아산사회복지재단 표적화된 유전자 전달을 위한 아데노-부속 바이러스 혈청형5 벡터를 포함하는 조성물
US20110052666A1 (en) * 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
DK3693025T3 (da) * 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
WO2013159036A1 (en) * 2012-04-19 2013-10-24 Oregon Health & Science University Adeno associated virus plasmids and vectors
WO2014124282A1 (en) * 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies

Similar Documents

Publication Publication Date Title
Drag et al. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions
JP7007273B2 (ja) 遺伝子治療用の改良された複合型二重組換えａａｖベクターシステム
US20220002749A1 (en) Multiple vector system and uses thereof
JP6873907B2 (ja) 遺伝性眼疾患を治療するための方法及び組成物
ES2704677T3 (es) Suministro eficaz de genes grandes por vectores de AAV duales
JP2021097675A (ja) 中枢神経系を標的化したａａｖベクター
JP7226801B2 (ja) 標的遺伝子導入のための方法および組成物
EP3413928B1 (en) Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
EP3013946B1 (en) Methods for expressing a polynucleotide of interest in the retina of a subject
AU2017227776C1 (en) AAV vectors for treatment of dominant retinitis pigmentosa
US20090011040A1 (en) Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CA3182080A1 (en) Viral vectors for the treatment of retinal dystrophy
JP2022529782A (ja) シュタルガルト病（ａｂｃａ４）の遺伝子治療
WO2021076941A9 (en) Gene therapy for alzheimer's disease
US20250026795A1 (en) Functional aav capsids for intravitreal administration
Agrawal et al. Ocular delivery of viral vectors for retinal and choroidal vascular diseases: a review
JP2023510186A (ja) Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療
US20260041791A1 (en) Compositions and methods for treatment of achromotopsia
JP2026503049A (ja) 眼疾患のための遺伝子療法
WO2025231487A1 (en) Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration
Class et al. Patent application title: Methods for Expressing a Polynucleotide of Interest in the Retina of a Subject Inventors: Deniz Dalkara (Paris, FR) Alvaro Rendon Fuentes (Paris, FR) Jose Alain Sahel (Paris, FR) Ophelie Vacca (Paris, FR)
Shukla et al. Site-Specific Ocular Nucleic Acid Delivery